Event Information
Title:
The Role of Mass Spectrometry in Clinical Molecular Testing and Personalized Genomics
Type:
Seminar
Sponsor:
Department of Biological Chemistry
Special Guest Seminar
Lecturer:
Dr. Charles Cantor
Chief Scientific Officer, SEQUENOM Inc.
Date:
Monday, March 11, 2013
Time:
12:30 - 14:00
Location:
Arthur and Rochelle Belfer Building for Biomedical Research, Auditorium
Contact:
Special Guest Seminar:
The Role of Mass Spectrometry in Clinical Molecular Testing and Personalized Genomics
Charles Cantor, Ph.D.
Chief Scientific Officer, SEQUENOM, Inc.
Monday March 11th at 12:30
Botnar auditorium, Belfer building
For more details please contact Dorit Mayer (Eldan) doritm@eldan.biz
Nucleic acid mass spectrometry can analyze dozens of loci at once in a variety of clinical samples. In this lecture I will focus on recent applications in cancer which take advantage of the tremendous sensitivity and quantitative precision of this technique. A major focus is the detection of somatic mutations that drive the properties of a tumor. These can be detected routinely in various types of biopsies and more recently in plasma from a tumor- bearing individual. In biopsies it is also possible to assess the clonality of the tumor cells. These measurements are an important input in choosing the right therapy for an individual patient. The same tools can also be used to study DNA methylation in samples of tumor and detected tumor-specific methylation patterns in DNA circulating in plasma.
Hosted by: Dr. Daniela Amann Zalcenstein, Head of the Crown Institute for Genomics, The Israel National Center for Personalized Medicine (INCPM).
Light refreshment will be served before the seminar
The Role of Mass Spectrometry in Clinical Molecular Testing and Personalized Genomics
Charles Cantor, Ph.D.
Chief Scientific Officer, SEQUENOM, Inc.
Monday March 11th at 12:30
Botnar auditorium, Belfer building
For more details please contact Dorit Mayer (Eldan) doritm@eldan.biz
Nucleic acid mass spectrometry can analyze dozens of loci at once in a variety of clinical samples. In this lecture I will focus on recent applications in cancer which take advantage of the tremendous sensitivity and quantitative precision of this technique. A major focus is the detection of somatic mutations that drive the properties of a tumor. These can be detected routinely in various types of biopsies and more recently in plasma from a tumor- bearing individual. In biopsies it is also possible to assess the clonality of the tumor cells. These measurements are an important input in choosing the right therapy for an individual patient. The same tools can also be used to study DNA methylation in samples of tumor and detected tumor-specific methylation patterns in DNA circulating in plasma.
Hosted by: Dr. Daniela Amann Zalcenstein, Head of the Crown Institute for Genomics, The Israel National Center for Personalized Medicine (INCPM).
Light refreshment will be served before the seminar